Equillium Gets Australian Clearance for Phase 1 Trial of Ulcerative Colitis Drug Candidate EQ504

MT newswire2026/10/05 21:06

05:06 PM EDT, 10/05/2026 (MT Newswires) -- Equillium (EQ) said Monday it received ethics committee approval and regulatory clearance in Australia for a Phase 1 trial of EQ504, an oral drug it is developing for ulcerative colitis, and expects to begin dosing healthy participants by early November. The company received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration under the Clinical Trial Notification scheme. The randomized, double-blinded, placebo-controlled, single-center trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral EQ504 doses ranging from 0.1 mg to 3.0 mg. Equillium said that, subject to supportive Phase 1 data, it expects to start a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned

According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.

智通财经•2026/11/09 11:09

Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October

FXStreet•2026/11/09 10:57

The UK Financial Conduct Authority allows banks to submit applications for crypto-related businesses.

AiCoin•2026/11/09 10:45

SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26